Sernova president and CEO Philip Toleikis said the broad claims in this patent position them with the ability to expand platform to a wide range of therapeutic cell types important in treating chronic disease.
"Broadening our patent portfolio also positions us to maximize partnering and development opportunities as we continue to advance our Cell Pouch System toward human clinical studies," Toleikis said.
The Cell Pouch System can be used as an effective platform for delivery of insulin from both autograft (self) and allograft (donor) islets to restore glucose control in stringent preclinical models of diabetes.
Sernova plans to explore the additional utility of the Cell Pouch System as an enabling platform for a range of therapeutic cell types with the potential to treat a number of chronic debilitating diseases representing broad unmet medical needs.
